Subclinical Hypothyroidism Symptoms: What Could Be Causing Them

What Subclinical Hypothyroidism Actually Means

Subclinical hypothyroidism is a laboratory diagnosis. TSH rises above the upper reference limit while free thyroxine (free T4) stays within normal range, indicating the pituitary gland is working harder to maintain adequate thyroid hormone output. The 2012 American Thyroid Association (ATA) and American Association of Clinical Endocrinologists (AACE) guidelines define SCH as a TSH between approximately 4.5 and 10 mIU/L with normal free T4 1.

The condition affects 4 to 10% of the general adult population according to large cross-sectional surveys, including the NHANES III dataset (N=16,533), which found SCH prevalence of 4.3% across the U.S. population 2. Prevalence climbs sharply with age. Women over 60 show rates between 15% and 20%.

The challenge is that many people with SCH feel entirely normal. Others report fatigue, mild weight gain, or cognitive sluggishness that they attribute to aging or stress. This overlap between SCH symptoms and common non-thyroidal complaints is what makes the condition both underdiagnosed and overdiagnosed depending on the clinical setting.

Hashimoto Thyroiditis: The Leading Cause

Chronic autoimmune thyroiditis (Hashimoto disease) accounts for the majority of SCH cases in iodine-sufficient countries. The immune system generates antibodies against thyroid peroxidase (TPO) and, less commonly, thyroglobulin. These antibodies gradually destroy thyroid tissue, causing a slow decline in hormone production that the pituitary compensates for by raising TSH.

The Whickham Survey, a landmark 20-year prospective cohort from the UK (N=2,779), demonstrated that women with elevated TPO antibodies had an annual risk of 4.3% for progressing to overt hypothyroidism, compared to 2.6% with elevated TSH alone 3. When both elevated TSH and positive TPO antibodies are present, the progression risk multiplies.

TPO antibodies are detectable in 60 to 80% of patients with SCH. Their presence changes the clinical calculus: a patient with TSH of 7 mIU/L and positive TPO antibodies is far more likely to progress to overt disease than a patient with the same TSH and negative antibodies. The ATA recommends checking TPO antibodies in all patients with newly identified SCH to guide monitoring frequency and treatment decisions 1.

Family history matters too. First-degree relatives of patients with autoimmune thyroid disease carry a threefold to fivefold increase in risk. If your mother or sister has Hashimoto disease, the odds of your elevated TSH reflecting early autoimmune thyroiditis rise considerably.

Medications That Raise TSH

Several commonly prescribed drugs can push TSH above normal without indicating primary thyroid gland failure.

Lithium reduces thyroid hormone synthesis and release. A meta-analysis published in the Journal of Clinical Psychiatry found that lithium-treated patients develop SCH at rates between 10% and 34%, depending on treatment duration and iodine status 4. Patients on lithium require thyroid function testing every 6 to 12 months.

Amiodarone is iodine-rich (each 200 mg tablet contains approximately 75 mg of organic iodine). It causes SCH in 5 to 25% of treated patients through the Wolff-Chaikoff effect, where iodine excess temporarily suppresses hormone synthesis 5. Some patients develop overt hypothyroidism; others remain subclinical for years.

Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) trigger autoimmune thyroiditis as an immune-related adverse event. Thyroiditis from checkpoint inhibitors typically presents first as transient thyrotoxicosis, then progresses to SCH or overt hypothyroidism within 6 to 12 weeks. Incidence varies from 5% to 10% across trials 6.

Other medications that can raise TSH include interferon-alpha, tyrosine kinase inhibitors (sunitinib, sorafenib), and high-dose biotin supplements (which interfere with TSH immunoassays rather than actual thyroid function, producing falsely abnormal results).

Iodine Status: Too Little or Too Much

Iodine intake has a U-shaped relationship with thyroid dysfunction. Populations with severe iodine deficiency develop goiter and hypothyroidism. But populations with iodine excess also show higher rates of SCH and autoimmune thyroiditis.

A 2006 cross-sectional study from China (N=3,761) compared thyroid disease prevalence across three regions with different iodine intakes. The region with excessive iodine intake (median urinary iodine 651 µg/L) had a significantly higher prevalence of SCH (16.7%) compared to the mildly deficient region (3.8%) 7. Excess iodine appears to accelerate autoimmune thyroid destruction in genetically susceptible individuals.

In practical terms, this means that kelp supplements, iodine-rich cough syrups, and contrast dye from CT scans can all transiently raise TSH. Patients with borderline thyroid function are most vulnerable. A single CT with iodinated contrast can cause a TSH spike lasting 4 to 8 weeks in susceptible individuals.

Non-Thyroidal Illness and Transient TSH Elevations

Not every elevated TSH reading signals a thyroid problem. Acute illness, recovery from illness, sleep deprivation, and circadian variation all affect TSH levels.

TSH follows a diurnal pattern, peaking between midnight and 4 AM and reaching its nadir in the late afternoon. A blood draw at 8 AM may yield a TSH of 5.5 mIU/L that would measure 3.2 mIU/L if repeated at 3 PM 8. This normal fluctuation means a single borderline TSH reading should always be confirmed with a repeat test drawn 6 to 8 weeks later, as recommended by the ATA 1.

Recovery from non-thyroidal illness (the "euthyroid sick syndrome" recovery phase) can produce a temporary TSH overshoot above normal range for several weeks. Hospitalized patients commonly show this pattern. Testing thyroid function within 6 weeks of an acute illness is unreliable for diagnosing SCH.

Adrenal insufficiency, untreated, can also raise TSH modestly. Cortisol normally suppresses TSH secretion, so when cortisol is low, TSH drifts upward. This is uncommon but worth considering in a patient with fatigue, low blood pressure, and unexplained mild TSH elevation.

Age, Obesity, and the Shifting TSH Reference Range

The "normal" TSH range is not fixed across populations. It drifts upward with age. The NHANES III data show that the 97.5th percentile for TSH rises from 4.12 mIU/L in 20- to 29-year-olds to 5.90 mIU/L in those over 80 2. Using a single upper limit of 4.5 mIU/L for all age groups misclassifies a substantial number of healthy older adults as having SCH.

Dr. Anne Cappola, an endocrinologist at the University of Pennsylvania and lead author of several thyroid studies, has stated: "Applying a single TSH cutoff across all ages leads to overdiagnosis in the elderly, where a TSH of 6 or 7 may be entirely physiologic" 9.

Obesity independently raises TSH. Leptin, produced by adipose tissue, stimulates TRH release from the hypothalamus, which in turn drives TSH production. Studies show that TSH decreases after bariatric surgery in parallel with weight loss, confirming that the elevated TSH was a consequence of obesity, not a cause 10. Treating an obese patient's TSH of 6 mIU/L with levothyroxine when the root issue is weight-driven TSH elevation is a common clinical misstep.

Symptoms: Real but Nonspecific

The symptom profile of SCH, when symptoms are present at all, overlaps almost completely with fatigue syndromes, depression, perimenopause, and normal aging. The most commonly reported symptoms include fatigue (reported by 30 to 40% of patients), mild weight gain (typically 2 to 5 kg), constipation, dry skin, cold intolerance, and difficulty concentrating.

The Colorado Thyroid Disease Prevalence Study (N=25,862) found that patients with SCH reported more symptoms than euthyroid controls, but the difference was modest, with an average of 3.7 symptoms versus 2.9 symptoms on a 12-item thyroid symptom questionnaire 11. The overlap means symptoms alone cannot confirm or exclude the diagnosis.

A 2018 systematic review and meta-analysis in the European Thyroid Journal (12 studies, N=36,189) found that fatigue, weight gain, and depressive symptoms were more common in SCH versus euthyroid controls, but the effect sizes were small (standardized mean difference 0.15, 0.30) 12. This creates a difficult clinical situation: patients feel genuinely unwell, but the TSH elevation may or may not be the reason.

Cognitive symptoms deserve specific attention. A subset of patients with SCH report "brain fog," slowed processing speed, and poor working memory. The Maastricht Aging Study found mild cognitive impairment associated with SCH in adults under 75, but not in older adults, consistent with the theory that age-related TSH shifts are physiologic in the elderly 13.

When Treatment Is Warranted

Not everyone with SCH needs levothyroxine. The decision depends on TSH level, symptoms, antibody status, age, cardiovascular risk, and pregnancy status.

The 2013 European Thyroid Association guidelines recommend levothyroxine for adults under 65 to 70 with TSH persistently above 10 mIU/L 14. For TSH between 4.5 and 10 mIU/L, treatment is individualized based on symptoms and antibody status. In adults over 80, the guidelines explicitly advise against treatment for TSH values below 10 mIU/L, citing evidence from the TRUST trial.

The TRUST trial (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism, N=737, mean age 74.4) randomized elderly patients with SCH to levothyroxine versus placebo for 12 months. The results showed no improvement in hypothyroid symptoms or fatigue scores with treatment 15. This was a key finding. Dr. David Stott, the trial's principal investigator, noted: "In older adults with subclinical hypothyroidism, levothyroxine provided no apparent benefits."

Pregnancy is the exception where aggressive treatment is universally recommended. SCH in pregnancy (TSH above 4.0 mIU/L or above the trimester-specific upper limit) is associated with increased risk of miscarriage, preeclampsia, and preterm delivery. The 2017 ATA pregnancy guidelines recommend levothyroxine when TSH exceeds 4.0 mIU/L in pregnant women, with lower thresholds (2.5 mIU/L) for those with positive TPO antibodies 16.

Starting doses for SCH are typically 25 to 50 mcg daily, lower than the 1.6 mcg/kg doses used in overt hypothyroidism. The goal is to restore TSH to the lower half of the reference range (0.5, 2.5 mIU/L) without causing iatrogenic thyrotoxicosis, particularly in elderly patients where overtreatment increases atrial fibrillation and osteoporosis risk.

Cardiovascular Risk and the TSH Threshold

The cardiovascular implications of SCH depend heavily on how high TSH climbs. An individual-participant data meta-analysis from the Thyroid Studies Collaboration (11 prospective cohorts, N=55,287) found that coronary heart disease events increased significantly only when TSH exceeded 10 mIU/L (hazard ratio 1.89 to 95% CI 1.28, 2.80) 17. For TSH between 4.5 and 6.9, there was no significant increase in cardiovascular events or mortality.

SCH is associated with elevated LDL cholesterol. A cross-sectional analysis from the Rotterdam Study found that LDL was 9 to 14 mg/dL higher in women with SCH versus euthyroid controls 18. Some trials have shown that levothyroxine treatment reduces LDL by 5 to 10% in SCH patients, which provides a secondary rationale for treatment in patients with borderline TSH who also carry cardiovascular risk factors.

Heart failure is another consideration. The Health ABC Study (N=3,044, adults aged 70, 79) showed that SCH with TSH above 7.0 mIU/L was associated with a twofold increase in congestive heart failure incidence over 4 years of follow-up 19. This finding reinforces that the "watch and wait" approach is most appropriate for lower TSH elevations, while persistently elevated TSH above 7, 10 mIU/L warrants more proactive management.

Monitoring Without Medication

For patients who do not meet treatment criteria, structured monitoring is the standard of care. The ATA recommends repeating TSH (and free T4 if previously borderline) every 6 to 12 months in patients with SCH and positive TPO antibodies, and annually in antibody-negative patients 1.

Patients should be counseled about symptoms that suggest progression to overt hypothyroidism: worsening fatigue that does not respond to sleep, unexplained weight gain exceeding 5 kg over 3 to 6 months, new-onset constipation, hair thinning, and menstrual irregularity in premenopausal women. Any of these should prompt a TSH recheck rather than waiting for the next scheduled test.

Lifestyle factors can modestly influence thyroid function. Selenium supplementation (200 mcg/day) has shown small reductions in TPO antibody titers in several randomized trials, including a Greek study (N=169) that demonstrated a 21% reduction at 6 months, though TSH was not significantly affected 20. The clinical significance of antibody reduction without TSH change remains uncertain, and the Endocrine Society does not currently recommend routine selenium supplementation for Hashimoto thyroiditis.

Repeat testing at 6 to 12 months shows spontaneous TSH normalization in up to 50% of patients with initial TSH between 4.5 and 7.0 mIU/L, reinforcing the importance of confirming the diagnosis before committing to lifelong thyroid hormone replacement 1.